Compare MSAI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSAI | NXL |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | 21 | 8 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.2M |
| IPO Year | N/A | N/A |
| Metric | MSAI | NXL |
|---|---|---|
| Price | $5.33 | $0.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $110.00 | N/A |
| AVG Volume (30 Days) | 32.7K | ★ 223.0K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $98.45 | $15.52 |
| Revenue Next Year | $38.89 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.31 |
| 52 Week High | $7.94 | $2.00 |
| Indicator | MSAI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 55.12 |
| Support Level | $4.88 | $0.35 |
| Resistance Level | $5.84 | $0.49 |
| Average True Range (ATR) | 0.40 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 59.62 | 72.11 |
MultiSensor AI Holdings Inc builds and deploys integrated condition monitoring and early threat detection solutions through a unified edge-to-cloud software architecture, delivering AI-powered connected intelligence and analytics for asset reliability and performance. The Company's platform integrates multiple sensing modalities such as thermal, visual, and vibration to detect mechanical, electrical, and other modes of asset failure, enabling organizations operating high-throughput, automation-rich, and power-dense facilities to protect uptime, enhance safety, and extend the useful life of their critical assets.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.